# DKSH Acquires Rocephin Brand Rights From Roche Across 80-Plus Markets

The antibiotic brand generated about 61 million Swiss francs in 2025 sales, according to DKSH.

By Will Langan | 24X7 News
Published: 2026-10-28T09:10:59.647Z
Updated: 2026-10-28T09:10:59.647Z
Section: Business
Format: News
Canonical: https://24x7news.us/articles/dksh-rocephin-rights-acquisition-roche-october-28-2026

DKSH said October 28 that it had acquired rights to Roche’s Rocephin antibiotic brand across more than 80 markets in Asia Pacific, Europe, Africa, the Middle East and Latin America.

The announcement did not disclose a purchase price. DKSH said the acquired brand generated approximately 61 million Swiss francs in net sales during 2025.

Rocephin contains ceftriaxone and was originally developed by Roche in Switzerland. DKSH said several major markets covered by the transaction overlap with its existing commercial operations, and that it already commercializes the brand in certain markets.

The transaction expands DKSH Healthcare’s portfolio of owned pharmaceutical brands. It follows the acquisition of Bayer’s Meliane brand announced in July, according to the company.

DKSH’s healthcare business distributes pharmaceuticals, consumer-health products and medical devices. The unit reported 2025 net sales of 5.8 billion Swiss francs.

Source: DKSH, October 28 acquisition announcement distributed through EQS News.

## Sources
- DKSH — Rocephin Rights Acquisition Announcement, EQS News: https://www.eqs-news.com/de/news/corporate/dksh-expands-its-healthcare-own-brands-portfolio-with-the-acquisition-of-rocephin-from-roche/27299b3b-3b28-48e7-899f-fde70bf39966_en